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AbstrAct
background Mother-to-child transmission (MTCT) of 
syphilis and HIV continue to be important yet preventable 
causes of perinatal and infant morbidity and mortality.
Objectives To systematically review, critically appraise 
and perform a meta-analysis to evaluate the operational 
characteristics of dual rapid diagnostic tests (RDTs) for 
HIV/syphilis and evaluate whether they are cost effective, 
acceptable and easy to use.
Design Systematic review and meta-analysis.
Data sources We searched seven electronic 
bibliographic databases from 2012 to December 2016 
with no language restrictions. Search keywords included 
HIV, syphilis and diagnosis.
review methods We included studies that evaluated 
the operational characteristics of dual HIV/syphilis 
RDTs. Outcomes included diagnostic test accuracy, 
cost effectiveness, ease of use and interpretation and 
acceptability. All studies were assessed against quality 
criteria and assessed for risk of bias.
results Of 1914 identified papers, 18 were included 
for the meta-analysis of diagnostic accuracy for HIV and 
syphilis. All diagnostic accuracy evaluation studies showed a 
very high sensitivity and specificity for HIV and a lower, yet 
adequate, sensitivity and specificity for syphilis, with some 
variation among types of test. Dual screening for HIV and 
syphilis was more cost effective than single rapid tests for 
HIV and syphilis and prevented more adverse pregnancy 
outcomes. Qualitative data suggested dual RDTs were 
highly acceptable to clients, who cited time to result, cost 
and the requirement of a single finger prick as important 
characteristics of dual RDTs.
conclusion The results of this systematic review and 
meta-analysis can be used by policy-makers and national 
programme managers who are considering implementing 
dual RDTs for HIV and syphilis.
trial registration number PROSPERO 
2016:CRD42016049168
IntrODuctIOn
Approximately 1.5 million pregnant women 
annually are infected with HIV, and 900 000 are 
infected with syphilis.1 2 Mother-to-child transmis-
sion (MTCT) of HIV and syphilis remain signifi-
cant causes of perinatal morbidity and mortality.3 
HIV MTCT can occur during pregnancy, delivery 
or breastfeeding. Without any intervention, HIV 
MTCT rates vary between 20% and 35% in 
breastfed infants or 15% and 20% for non-breastfed 
infants.4 However, these MTCT rates for HIV can 
be reduced to less than 5% on provision of effective 
intervention.5 Untreated maternal syphilis results 
in in-utero infection, associated with significant 
adverse pregnancy outcomes, such as stillbirth, , 
preterm and low birth weight, neonatal death and 
clinical syphilis infection in infants born alive.6 
Systematic reviews indicate that in pregnant women 
with untreated syphilis, more than half of pregnan-
cies result in these adverse outcomes,7 and that an 
even higher proportion of pregnancies are affected 
in women with primary or secondary syphilis infec-
tions.8 Prenatal syphilis screening followed by treat-
ment with injectable penicillin early in pregnancy 
effectively treats the pregnant woman and prevents 
congenital syphilis. In addition, maternal syphilis 
has been shown to increase the risk of MTCT of 
HIV.9 The WHO launched a global initiative for 
elimination of congenital syphilis in 20078 and has 
also prioritised the elimination of mother to child 
transmission (EMTCT) of HIV.5 Additionally in 
2014, WHO HIV and STI programmes in collab-
oration with other UN partners joined forces to 
validate countries for the elimination of EMTCT 
of HIV and syphilis using shared guidelines and 
processes.5 10 Several countries have now achieved 
validation of EMTCT for HIV and/or syphilis.11
Screening all pregnant women for syphilis and 
HIV at first antenatal care visit is recommended 
in nearly all countries of the world and is being 
scaled up rapidly in countries committed to 
EMTCT of HIV and syphilis.12 13 However, while 
the testing of pregnant women for HIV is relatively 
well resourced, syphilis-infected pregnant women 
often go undiagnosed and untreated. While many 
countries have antenatal syphilis screening policies, 
more than 350 000 adverse pregnancy outcomes 
occur annually due to untreated maternal syphilis, 
despite the low cost of testing and treatment.14 To 
meet current targets, calls have been made to accel-
erate the dual EMTCT of syphilis and HIV.15 Early 
diagnosis and treatment of both HIV and syphilis 
in pregnant women has been proven as an effective 
strategy in the prevention of both adverse outcomes 
of pregnancy and MTCT. Key populations, such as 
men who have sex with men (MSM), transgender 
people, injecting drug users and sex workers 
to cite: Gliddon HD, 
Peeling RW, Kamb ML, et al. 
Sex Transm Infect Published 
Online First: [please include 
Day Month Year]. doi:10.1136/
sextrans-2016-053069
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
sextrans- 2016- 053069).
2London Centre for 
Nanotechnology, University 
College London, London, UK
4Department of Clinical 
Research, Faculty of Infectious 
and Tropical Diseases, London 
School of Hygiene and Tropical 
Medicine, London, UK
3Division of STD Prevention, 
Center for Disease Control and 
Prevention, Atlanta, Georgia, 
USA
1Department of Reproductive 
Health and Research, World 
Health Organization, Geneva, 
Switzerland
correspondence to
Dr Melanie M Taylor, 
Department of Reproductive 
Health and Research, World 
Health Organization, 20 
Avenue Appia, Geneva 1211, 
Switzerland;  mtaylor@ who. int
Received 15 February 2017
Revised 7 April 2017
Accepted 29 April 2017
 STI Online First, published on July 26, 2017 as 10.1136/sextrans-2016-053069
Copyright Article author (or their employer) 2017. Produced by BMJ Publishing Group Ltd under licence. 
group.bmj.com on September 13, 2017 - Published by http://sti.bmj.com/Downloaded from 
2 Gliddon HD, et al. Sex Transm Infect 2017;0:1–13. doi:10.1136/sextrans-2016-053069
review
would also benefit from improved HIV and syphilis screening 
coverage,16–18 as described in key policy documents published 
by the WHO.19 20
In 2015, the SD BIOLINE HIV/Syphilis Duo Test (Standard 
Diagnostics, Korea) was accepted for the WHO list of prequal-
ified in vitro diagnostics.21 Other rapid diagnostics tests (RDTs) 
are also available that can simultaneously test for antibodies 
to HIV and Treponema pallidum antigens, ensuring that both 
tests can be conducted in a single visit to a single health facility. 
Herein, we describe a systematic review and meta-analysis of 
published literature to evaluate the operational characteristics of 
currently available RDTs for HIV and syphilis, including diag-
nostic accuracy, cost-effectiveness, acceptability and ease of test 
interpretation.
MethODs
eligibility criteria
We followed the preferred reporting items for systematic 
reviews and meta-analysis (PRISMA) guidelines.22 Studies were 
included that evaluated, in either laboratory or field settings, any 
commercially available RDT (that satisfies the specifications in 
the ASSURED criteria23 24) that simultaneously tests for HIV and 
syphilis on the same cartridge or device. Studies were included 
that involved any sexually active populations in any geographic 
location. The primary outcome was diagnostic test accuracy (ie, 
sensitivity, specificity, positive predictive value, negative predic-
tive value) for both HIV and syphilis. Secondary outcomes 
included cost-effectiveness, usability, ease of test interpretation 
and acceptability. The types of studies that were eligible for 
inclusion were evaluation studies, cost-effectiveness analyses 
and usability and acceptability studies. For the meta-analysis 
of diagnostic accuracy, studies were included if an acceptable 
reference standard for both HIV and syphilis was used (HIV: 
either enzyme immunoassay (EIA), Western blot (WB) or two 
RDTs; syphilis: Treponema pallidum particle agglutination assay 
(TPPA) or T. pallidum haemagglutination assay (TPHA) with or 
without non-treponemal testing). Studies were excluded if HIV 
and syphilis diagnosis were not conducted on a dual RDT (ie, 
on the same cartridge/device). Studies were included regardless 
of sample size.
search terms and strategy
We searched the following electronic bibliographic databases: 
Medline, Embase, KoreaMed, PAHO Library Catalogue, China 
National Knowledge Infrastructure, Russian Science Citation 
Index and J-stage. The search strategy included terms relating to 
HIV, syphilis and diagnosis (see online supplementary material). 
No language restrictions were used. Studies published between 
January 2012 and the December 2016 were sought. The searches 
were rerun immediately before the final analyses to check for 
recent relevant literature. Additional records were identified by 
searching bibliographies of relevant publications.
Data extraction
Titles and abstracts were checked for relevance. For the 
meta-analysis of diagnostic accuracy, the data extracted included 
study title, dates of enrolment, country, test(s) evaluated, labora-
tory or field evaluation (and if so, sample type used), the popu-
lation studied and for laboratory evaluations, whether fresh or 
archived specimens were used. For both the HIV and syphilis 
diagnosis components of each study, the following information 
was either extracted or calculated using two by two tables: the 
number of participants/samples used, prevalence (%), reference 
standard test, number of true positives, false positives, false 
negatives and true negatives. Study investigators were contacted 
if further information was required.
Two reviewers (HDG and MMT) independently extracted 
data from the included studies. Disagreements were resolved by 
consensus or by consulting external advisors. The updated stand-
ards for the reporting of diagnostic accuracy studies (STARD) 
checklist25 26 was used to evaluate the methodology of included 
studies. To critically appraise the included evaluation studies, the 
quality assessment of diagnostic accuracy studies (QUADAS-2) 
checklist27 was used.
Data synthesis
Forest plots and summary receiver operating characteristic 
(SROC) curves were constructed using RevMan.28
results
study characteristics
Among the 1914 records identified and screened (figure 1), 
we included 28 studies for the data synthesis, and 18 of these 
were also used in the meta-analysis. Two-by-two table data 
were not available for one study.29 Two studies included in the 
meta-analysis evaluated the performance of multiple tests. Diag-
nostic accuracy studies evaluated the performance of the SD 
BIOLINE HIV/Syphilis Duo Test, the MedMira Multiplo Rapid 
TP/HIV Antibody Test (MedMira, Canada) and the Chembio 
Dual Path Platform (DPP) HIV/Syphilis Assay (Chembio Diag-
nostic Systems, USA) (table s1). These studies were conducted 
in a range of WHO regions including Africa (South Africa, 
Kenya, Nigeria, Malawi, Ghana, Togo), South-East Asia (Nepal, 
Myanmar), the Western Pacific (China, Lao People’s Democratic 
Republic) and the Americas (Haiti, Peru, Mexico, USA). The 
populations studied were primarily key populations (such as sex 
workers, injection drug users (IDUs), transgender women, MSM 
and sexually STD clinic attendees). Three studies evaluated the 
diagnostic accuracy of the test in antenatal care settings.
Included and excluded studies
The 18 diagnostic accuracy studies that were included in the 
meta-analysis for diagnostic accuracy are detailed in table 1. The 
median sample sizes were 415 and 450 for HIV and syphilis, 
respectively, with the range for each falling between 150 and 
10 000.30–47
One study was identified that evaluated the diagnostic accu-
racy of the INSTI Multiplex downward-flow immunoassay48 
(also called the INSTI Multiplex HIV-1/HIV-2/Syphilis Antibody 
Test) (bioLytical Laboratories, Canada). Using 200 archived 
serum specimens from high-risk individuals in Peru, the results 
of this study suggested a high sensitivity (100%, 95% CI 95.9% 
to 100%) and specificity (95.5%, 95% CI 89.9% to 98.5%) for 
HIV diagnosis and a slightly lower sensitivity (87.4%, 95% CI 
81.4% to 92.0%) but a higher specificity (97%, 95% CI 84.2% 
to 99.9%) for syphilis diagnosis. These results were not included 
in the meta-analysis because only one diagnostic accuracy eval-
uation study for this diagnostic test was identified. A study 
published by Leon et al40 evaluated visual interpretation of the 
Chembio DPP HIV/Syphilis Assay compared with the use of 
an electronic reader to interpret the test.40 The sensitivity and 
specificity for the HIV component of the Chembio DPP HIV/
Syphilis Assay did not alter according to whether visual inter-
pretation or electronic reader was used. The sensitivity of the 
syphilis component was similarly unaffected, but the specificity 
was slightly lower when the electronic reader was used (99.7%, 
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95% CI 98.2% to 100%) compared with visual interpretation 
(100%, 95% CI 98.8% to 100%), although this was not statis-
tically significant. Results for test interpretation using the elec-
tronic reader were not included in the meta-analysis.
Hess et al32 studied the performance of the Chembio DPP HIV/
Syphilis lateral flow assay in its original configuration (in which 
the liquid first flowed across the syphilis test line, followed by 
the HIV test line), and also in a revised or ‘reversed’ configu-
ration (HIV followed by syphilis). This revised form of the test 
became the final approved model of the test. The Hess et al32 
study reported two sets of sensitivities and specificities for the 
original order of the test and the reverse order. Only the results 
of the reverse order (which has since become the standard order 
for the test) were included in the meta-analysis. The study by 
Hess et al32 also assessed the performance of an integrated test 
for HIV, hepatitis C virus (HCV) and syphilis on a single diag-
nostic platform (Chembio DPP HIV-HCV-Syphilis Assay); but 
these results were not included in the meta-analysis because no 
other studies were identified that evaluated this particular RDT.
The meta-analysis stratification strategy is detailed in online 
supplementary figure 1. Tests were first stratified by manu-
facturer (figure 2), by evaluation setting (laboratory or field) 
(figure 3) and by specimen type used for evaluation (including 
serum versus whole blood, and archived versus fresh specimens) 
(figures 4 and 5).
Diagnostic accuracy of hIV and syphilis by rDt manufacturer
HIV diagnostic performance by manufacturer
The diagnostic accuracy for HIV and syphilis of RDTs produced 
by three different manufacturers are detailed in figure 2. There 
were 12 studies that evaluated the SD BIOLINE HIV/Syphilis 
Duo Test, four studies that assessed the MedMira Multiplo Rapid 
TP/HIV Antibody Test and six that appraised the Chembio DPP 
Figure 1 PRISMA flow diagram showing the number of records initially identified and that were subsequently excluded or included in the meta-
analysis on the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. PRISMA, preferred reporting items for 
systematic reviews and meta-analysis.
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HIV/Syphilis Assay, although one of these, reported by Bowen et 
al46 only reported the accuracy of syphilis diagnosis.
All but one of the evaluation studies reported a sensitivity of 
HIV diagnosis of at least 98%. This study, by Bristow et al,43 
reported a sensitivity of 94% for the MedMira Multiplo Rapid 
TP/HIV Antibody Test. The specificity values for HIV diagnosis 
range from 97% to 100% for the SD BIOLINE HIV/Syphilis 
Duo Test and 92% to 100% for the MedMira Multiplo Rapid 
TP/HIV Antibody Test. All of the specificity values for HIV diag-
nosis reported for the Chembio DPP HIV/Syphilis Assay were 
100% (figure 2A).
The summary ROC curves for the three test manufacturers are 
presented in figure 2C, and D. Summary HIV ROC curve for 
the MedMira Multiplo Rapid TP/HIV Antibody test falls slightly 
Figure 2 Meta-analysis of the diagnostic accuracy of dual HIV/syphilis RDTs, stratified according to manufacturer. Forest plots are sown for the 
diagnostic accuracy of (A) HIV and (B) syphilis diagnosis. Summary ROC curves are shown for the diagnosis of (C) HIV and (D) syphilis. RDTs, rapid 
diagnostic tests; ROC, receiver operating characteristic.
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below that of the curve for the SD BIOLINE HIV/Syphilis Duo 
Test and Chembio DPP HIV/Syphilis Assay, indicating that this test 
might have a lower diagnostic performance for HIV (figure 2C).
Syphilis diagnostic performance by manufacturer
For syphilis diagnosis, the reported sensitivities for the SD 
BIOLINE HIV/Syphilis Duo Test were all between 89% and 
100%, except for one study published by Black et al,45 which 
reported a sensitivity of 67%. The authors of this study noted 
that patients with a rapid plasma regain (RPR) titre of ≥1:4 
(an indicator of active syphilis) were more likely to test positive 
using this RDT. The specificity values reported for syphilis diag-
nosis using SD BIOLINE HIV/Syphilis Duo Test ranged from 
91% to 100% (figure 2B).
Figure 3 Meta-analysis of the diagnostic accuracy of dual HIV/syphilis RDTs, stratified according to the setting in which the evaluation was 
conducted. Forest plots are shown for the diagnostic accuracy of (A) HIV and (B) syphilis diagnosis. Summary ROC curves are shown for (C) HIV and 
(D) syphilis diagnosis. RDTs, rapid diagnostic tests; ROC, receiver operating characteristic.
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The ranges for sensitivity and specificity reported for the 
syphilis component of MedMira Multiplo Rapid TP/HIV Anti-
body Test were 81% to 95% and 93% to 100%, respectively.
Chembio DPP HIV/Syphilis Assay gave sensitivity ranges for 
syphilis diagnosis of 46% to 97%, although each evaluation 
study reported a specificity of 100%. Similar to the study by 
Black et al,45 of the SD Bioline HIV/Syphilis Duo Test syphilis 
component, Bowen et al46 also reported in their study of the 
Chembio DPP HIV/Syphilis Assay that patients with a high RPR 
titre (≥1:4) were more likely to test positive for presence of 
treponemal antibody.46
The summary ROC curve in figure 2D shows that SD BIOLINE 
HIV/syphilis Duo Test gives the highest syphilis diagnostic accu-
racy, followed by the Chembio DPP HIV/Syphilis Assay and then 
Figure 4 Meta-analysis of the diagnostic accuracy of dual HIV/syphilis RDTs, stratified according to the specimen type (serum or whole blood) used 
in the evaluation studies. Forest plots are shown for the diagnostic accuracy of (A) HIV and (B) syphilis diagnosis. Summary ROC curves are shown for 
(C) HIV and (D) syphilis diagnosis. RDTs, rapid diagnostic tests; ROC, receiver operating characteristic.
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Figure 5 Meta-analysis of the diagnostic accuracy of dual HIV/syphilis RDTs, stratified according to the specimen type (archived, ie, frozen 
specimens or fresh specimens). Forest plots are shown for the diagnostic accuracy of (A) HIV and (B) syphilis diagnosis. Summary ROC curves are 
shown for (C) HIV and (D) syphilis diagnosis. FN, false negative; FP, false positive; RDTs, rapid diagnostic tests; ROC, receiver operating characteristic; 
TN, true negative; TP, true positive.
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the MedMira Multiplo Rapid TP/HIV Antibody Test; however, 
these differences are not statistically significant.
Diagnostic accuracy for hIV and syphilis in laboratory and 
field settings
Diagnostic accuracy results were also stratified according to 
whether the evaluation study was conducted in a laboratory 
or field setting (figure 3). Field evaluations were typically 
conducted in sexual health facilities,32 41 42 45 including one that 
actively recruited pregnant women.42 Another was conducted in 
antenatal settings46 and another at outreach sites for key popu-
lations.43 Results were combined, regardless of brand name or 
manufacturer.
HIV diagnostic performance in lab and field settings
In laboratory settings, the sensitivity of HIV diagnosis ranged 
from 94% to 99%, and specificity from 92% to 100%. In field 
settings, reported HIV sensitivity values were between 96% and 
99% for all but one of the field evaluations. The sensitivity of 
HIV diagnosis in the remaining study, published by Bristow et 
al,43 was 94%. This study evaluated the MedMira Multiplo 
Rapid TP/HIV Antibody Test. The range for specificity of HIV 
diagnosis reported in field settings was 97% to 100%.
Syphilis diagnostic performance in lab and field settings
For syphilis diagnosis, reported sensitivities ranged from 93% 
to 100% in laboratory settings, whereas for field settings, they 
ranged from 47% to 96%. The sensitivity value of 47% for 
syphilis diagnosis was reported by Hess et al32 for the Chembio 
DPP HIV/Syphilis Assay. In this study, only 11% of positive 
TPPA cases were RPR reactive, suggesting that the majority of 
cases represented previously treated rather than active syphilis 
infection. The next two lowest sensitivity values were reported 
by Black et al45 (67%) and Bowen et al46 (69%) for the SD 
BIOLINE HIV/Syphilis Duo Test and the Chembio DPP HIV/
Syphilis Assay, respectively. Both Black et al45 and Bowen et 
al46 also reported on results of TPPA+/RPR+ test results as a 
standard, distinguishing between RPR titres >1:4 and <1:4 as 
indicators of active (transmissible) syphilis infection and old or 
treated infections (less transmissible), respectively.6 Both found 
the syphilis component of the DPP had high sensitivity and spec-
ificity in TPPA-reactive samples with higher RPR titres.
Using TPPA positivity as the standard, specificity values for 
syphilis diagnosis for the Chembio DPP HIV/Syphilis Assay 
ranged from 93% to 100% and 91% to 100% for laboratory and 
field settings, respectively.
Diagnostic accuracy of hIV and syphilis by specimen type
It is possible that sample composition (ie, whole blood or 
serum) and storage can affect the diagnostic accuracy of RDTs. 
Long-term storage of frozen serum can affect the stability of 
proteins and other constituents of the sample.49 To investigate 
the diagnostic accuracy according to whether evaluation studies 
used serum or whole blood, and archived or fresh specimens, 
results were stratified according to specimen type (figure 4 and 
figure 5). Results were combined, regardless of brand name or 
manufacturer.
HIV diagnostic performance by specimen type
Reported sensitivities for HIV diagnosis were lower for studies 
that used whole blood (94% to 99%)  compared with those 
that used serum (98% to 100%). However, studies using whole 
blood reported higher specificities (97% to 100%) than those 
using serum (92% to 100%) (figure 4A), leading to similar plot-
ting of SROC curves for studies using serum and whole blood 
(figure 4C).
For studies using archived specimens, the sensitivity of HIV 
diagnosis ranged from 98% to 100%, and specificity from 94% 
to 100%. When fresh specimens were used, HIV diagnosis sensi-
tivity values were between 94% and 100%, and specificity values 
were between 97% and 100% (figure 5A). Diagnostic accuracy 
for HIV was therefore minimally affected by specimen type.
Syphilis diagnostic performance by specimen type
Diagnostic accuracy for syphilis appears to be higher in studies 
that used serum rather than whole blood, with improved sensi-
tivity ranges being reported (between 93% and 100% for studies 
that used serum, compared with 47% and 96% for studies that 
used whole blood) and specificities (93% to 100% for studies 
using serum compared with 91% to 100% for studies that used 
whole blood) (figure 4B).
Studies that used archived specimens reported syphilis sensi-
tivities and specificities ranging from 93% to 100% and 97% 
to 100%, respectively. The diagnostic accuracy for syphilis was 
slightly poorer when fresh specimens were used, with sensitiv-
ities falling between 47% and 100% and specificities between 
91% and 100% (figure 5B). This could reflect the fact that the 
evaluations using archived specimens were conducted in labora-
tory settings.
secondary outcomes
Cost-effectiveness and impact on adverse pregnancy outcomes
A study by Bristow et al50 showed that dual HIV/syphilis RDTs 
are an efficacious means of reducing the number of adverse preg-
nancy outcomes compared with other screening algorithms. In 
this study, four screening algorithms were compared, including 
an HIV RDT only, dual HIV and syphilis rapid RDTs, single 
RDTs for both HIV and syphilis and finally, HIV and syphilis 
laboratory tests. Costs of prevention and care were calculated, 
showing that a dual HIV/syphilis rapid testing strategy was both 
the least costly (US$226.92 per pregnancy) and resulted in the 
fewest adverse pregnancy outcomes (15 370 per 100 000 preg-
nancies for dual HIV/syphilis testing compared with 15 820 for 
HIV rapid testing only, 15 779 for HIV rapid testing and syphilis 
laboratory testing and 15 778 for single, separate RDTs for HIV 
and syphilis).
Feasibility and acceptability
A qualitative study conducted among patients seeking STI, HIV 
testing or antenatal care in Haiti evaluated the importance of 
various factors for HIV and syphilis dual testing to patients.51 
The majority of study participants cited cost as the most 
important factor, but also selected single finger prick sampling 
and time to result as important attributes for dual testing. Inter-
estingly, pregnant women reported that they prioritised time to 
result over all other factors. In antenatal care (ANC) settings in 
Colombia, dual HIV/syphilis RDTs were shown to have similar 
acceptability values to patients compared with separate rapid 
tests for HIV and syphilis.52
From the service provider perspective, in both China and 
Nigeria, dual HIV/syphilis RDTs were found to be fairly easy or 
very easy to use and to interpret the results, as was reported by 
Yin et al.38 This study scored the SD BIOLINE HIV/Syphilis Duo 
Test, the Chembio DPP HIV/Syphilis Assay, and the MedMira 
Multiplo Rapid TP/HIV Antibody Test on a range of operational 
characteristics. The SD BIOLINE HIV/Syphilis Duo Test scored 
group.bmj.com on September 13, 2017 - Published by http://sti.bmj.com/Downloaded from 
10 Gliddon HD, et al. Sex Transm Infect 2017;0:1–13. doi:10.1136/sextrans-2016-053069
review
the highest out of the three, with significant advantages over 
other tests in clarity of kit instruction, ease of use, ease of inter-
pretation of results and training time required.
Cost-effectiveness, ease of test interpretation and acceptability of 
individual rapid tests for simultaneous HIV and syphilis diagnosis
Limited data were available on the cost effectiveness, usability, 
ease of test interpretation and acceptability of single device dual 
tests for dual HIV/syphilis diagnosis. However, the following 
studies were identified, which provide data for these factors 
when syphilis and HIV were diagnosed at the same time, using 
individual RDTs.
A systematic review that evaluated the impact of introducing 
rapid syphilis testing (RST) in antenatal care settings on HIV 
and syphilis uptake and coverage showed that RST may increase 
both syphilis and HIV screening rates in antenatal care settings.53 
Two studies cited by the review that supported this claim were 
conducted by Strasser et al54 in Uganda and Zambia, and by 
Fleming et al55 in ANC settings in rural Kenya. More recently, 
in Kampala, Uganda, the introduction of syphilis testing within 
integrated HIV-antenatal care settings was shown to be effective, 
feasible and successfully capitalised on programmes that have 
already been established and optimised for HIV care.56
The acceptability of simultaneous testing for HIV and syph-
ilis using separate RDTs was investigated in key populations 
in Peru.57 The tests used were the SD BIOLINE HIV 1/2 3.0 
and SD BIOLINE Syphilis 3.0 tests. Client perceptions and the 
feasibility of implementing simultaneous HIV and syphilis RDTs 
were evaluated. The proportion of clients tested who received 
timely results increased by 30.8% for HIV and 35.7% for syph-
ilis in pregnant women. The RDTs for HIV and syphilis allowed 
for fewer hospital visits, less time spent waiting at the hospital 
and lower labour and resource costs for the hospital. All clients 
tested were either completely satisfied (52%) or satisfied (48%) 
with the process of simultaneous HIV/syphilis testing. Seven-
ty-two per cent of study participants strongly agreed with the 
statement, ‘I liked the process of having the two tests taken at 
the same time’.
A study published by Owusu-Edusei et al58 simulated the 
cost-effectiveness of using separate laboratory-based diagnosis 
for HIV and syphilis in China. Their results suggested that 
incorporating syphilis screening into pre-existing antenatal 
HIV screening programmes was more cost-effective than HIV 
screening only even in very low prevalence settings, and that 
testing for both infections would prevent a larger number of 
adverse pregnancy outcomes.
Quality of studies
The STARD checklist was used to appraise the quality of reporting 
of studies included in the meta-analysis (see online supplemen-
tary file 1). Of the 30 items in the updated STARD checklist 
published by Bossuyt et al,26 some items were universally well 
reported, such as the identification as a study of diagnostic accu-
racy (100%), scientific and clinical background (100%), index 
test and reference standard methods (100%), methods for esti-
mating or comparing measures of diagnostic accuracy (94%) and 
implications for clinical practice (100%). However, other items 
were poorly reported, such as the rationale for choosing the 
reference standard where alternatives exist and whether clinical 
information and reference standard results were available to the 
performers of the index tests or if clinical information and index 
test results were available to assessors of the reference standard. 
In addition, few studies included a flow diagram of participants.
Quality of methodology was assessed using the QUADAS-2,27 
and results are summarised in online supplementary table 3. Most 
studies either scored as low or unclear risk of bias where patient 
selection, index tests and study flow and timing were concerned. 
In particular, studies were reported as having an unclear risk of 
bias for the reference standard if they did not state that results 
of the reference standard were interpreted without knowledge 
of the results of the index tests. Little concern was identified 
regarding the applicability of patients, index tests and reference 
standards used in the studies.
DIscussIOn
The overall purpose of this study was to evaluate the literature 
relating to dual RDTs for HIV and syphilis, particularly with 
regards to their diagnostic accuracy, cost-effectiveness, feasi-
bility, acceptability and ease of interpretation. This meta-anal-
ysis reviewed the results of 18 recently published studies on 
the performance characteristics of rapid dual HIV/syphilis tests 
when evaluated by manufacturer and performance in field versus 
laboratory settings. The diagnostic accuracy for HIV was found 
to vary minimally depending on test manufacturer, with SD 
BIOLINE HIV/Syphilis Duo Test and the Chembio DPP HIV/
Syphilis Assay showing the highest diagnostic accuracy. Diag-
nostic accuracy for syphilis varied with manufacturer, with the 
SD BIOLINE HIV/Syphilis Duo Test being the most accurate. 
Performance of the test in the laboratory versus field setting did 
not result in a difference in the sensitivity or specificity for HIV 
but a poorer sensitivity was noted in two field-based studies for 
syphilis. Published literature on the cost-effectiveness and feasi-
bility of dual RDTs for HIV and syphilis was limited but demon-
strated encouraging results that, along with performance results, 
could be used to support the use of these tests for screening of 
populations at risk for HIV and syphilis.
The diagnostic accuracy for HIV of each of the three dual tests 
(SD BIOLINE HIV/Syphilis Duo Test, MedMira Multiplo Rapid 
TP/HIV Antibody Test and the ChemBio DPP HIV/Syphilis 
Assay) evaluated in the meta-analysis was consistently high (with 
all studies but one reporting sensitivities of over 98% and all but 
two reporting specificities of over 97%). The diagnostic accu-
racy for HIV was found to be slightly lower for the MedMira 
Multiplo Rapid TP/HIV Antibody Test, which gave sensitivi-
ties of between 94% and 100% and specificities between 98% 
and 100%. In comparison, the SD BIOLINE HIV/Syphilis Duo 
Test and Chembio DPP HIV/Syphilis Assay gave higher levels 
of sensitivities, with a range of 98% to 100% for each. Their 
reported specificities were also higher, with 97%–100% for the 
SD BIOLINE HIV/Syphilis Duo Test and 98%–100% for the 
Chembio DPP HIV/Syphilis Assay. This was also true for syph-
ilis diagnostic accuracy, with the SD BIOLINE HIV/Syphilis Duo 
Test performing the best out of the three. It should be noted that 
single RDTs for syphilis have also shown sensitivities between 
64% and 100% and reduced sensitivities for clinic-based evalu-
ations compared with laboratory evaluations.54 A target product 
profile (TPP) for an ideal dual HIV/syphilis RDT was developed 
at the 1st Technical Consultation on Point-Of-Care Diagnostic 
Tests for Sexually Transmitted Infections convened by the WHO 
Reproductive Health Research Department in May 2001.59 This 
TPP set out the desired operational characteristics for a dual 
HIV/syphilis RDT and included minimal and optimal specifica-
tions for parameters such as sensitivity and specificity of HIV 
and syphilis diagnosis. The minimal sensitivity and specificity 
specifications were >98% and >98% for HIV, respectively, and 
>75% and >95%, respectively, for syphilis. The three RDTs 
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that were included in the meta-analysis all fulfil each of these 
requirements, at least at the minimal level. Minimum standards 
for HIV RDTs have been suggested to be >99% for sensitivity 
and >98% specificity.60
Accuracy of HIV diagnosis was minimally affected by 
conducting the test in the laboratory compared with field settings. 
However, a reduction in diagnostic accuracy was seen in field 
settings for syphilis. This was particularly true for the Chembio 
DPP HIV/Syphilis Assay. Two studies identified improvements 
in sensitivity when RPR titre values were included to identify 
active syphilis.41–43 45 46 This suggests that despite lower overall 
reported sensitivities, these tests may preferentially detect active 
syphilis over old or treated syphilis, which is clinically advan-
tageous. The SD Bioline HIV/Syphilis Test has received WHO 
prequalification21 and is ready for use according to country-es-
tablished quality performance measures. Our results indicate 
that, although the syphilis performance component as assessed 
from these studies still meets the minimal criteria as specified for 
the TPP, efforts to ensure consistent, correct and repeated staff 
training and quality control measures should be undertaken at 
the field level to ensure appropriate use and interpretation of 
these tests.
The overall diagnostic accuracy for HIV was minimally 
affected according to whether serum or whole blood was used 
in the evaluation studies. However, studies that used serum 
reported a superior diagnostic performance for syphilis than 
those that used whole blood. Specimen type (archived versus 
fresh specimens) was shown to marginally affect diagnostic accu-
racy for syphilis but not for HIV. These findings mimic those 
of the lab versus field analysis as all of the archived specimens 
would have been tested in a laboratory setting. However, the 
findings of the archived versus fresh analysis demonstrate the 
good performance of the RDTs on archived specimens.
Evidence from qualitative studies gives a strong indication 
that dual testing for HIV and syphilis is acceptable to testing 
clients, feasible for implementation in a range of ANC and other 
programmes and cost-effective. In a modelling study, when 
compared with HIV testing alone using a RDT, two separate 
RDTs for HIV and syphilis, and separate laboratory testing for 
HIV and syphilis, dual RDTs for HIV and syphilis were shown 
to be the least costly and also prevented the largest number 
of adverse pregnancy outcomes.50 A study conducted in Haiti 
assessed the importance of a range of RDT characteristics for 
testing clients. The most important factors included cost, the 
requirement for a single finger prick sample and time to result.51 
Published literature on simultaneous testing for HIV and syphilis 
using separate RDTs also provided evidence on the feasibility 
of implementation of incorporating syphilis testing into pre-ex-
isting HIV screening programmes, acceptability and cost-effec-
tiveness.53 56–58 Unfortunately, less data were available in the 
literature concerning ease of dual RDT interpretation.
Our meta-analysis has some limitations. First, our search 
criteria may have missed some studies and the authors are 
aware of ongoing studies for which results are not yet avail-
able. Second, to date only a limited number of diagnostic accu-
racy evaluation studies have been published for each dual RDT. 
While the best diagnostic performance was observed for the SD 
BIOLINE HIV/Syphilis Duo Test, more evaluation studies were 
available for this test compared with the two others included 
in the meta-analysis. More evidence is required to inform our 
understanding of the performance of the MedMira Multiplo 
Rapid TP/HIV Antibody Test and Chembio DPP HIV/Syphilis 
Assay. In particular, more field evaluation studies are warranted, 
particularly to assess the sensitivity of the syphilis component 
of the diagnostic tests under the conditions and using operators 
that are likely available in real world versus controlled, labora-
tory settings. Third, studies used a range of reference tests with 
which to evaluate the diagnostic accuracy of the dual RDTs. 
For example, some studies used treponemal tests (measuring 
ever exposure to T. pallidum, regardless of previous treatment) 
only, whereas others used both treponemal and non-treponemal 
tests (measuring active infection). Where archived specimens 
were used, studies did not mention when reference testing was 
carried out (ie, at the time of collection or at the same time 
as the index test), and this timing could affect the agreement 
between the results of reference and index test. Another limita-
tion is that for the studies that used archived specimens, it was 
unclear what population these specimens were taken from and 
in what setting. Too few studies were available for a reliable 
performance comparison of the RDTs with use of treponemal 
and non-treponemal tests (n=4) versus treponemal only as 
reference standards for syphilis diagnosis. This analysis may 
be considered for future study. Finally, only three commer-
cially available dual HIV/syphilis, RDTs were evaluated in this 
meta-analysis. However, other tests are available which we did 
not include in this analysis, such as the INSTI Multiplex HIV-1/
HIV-2/Syphilis Antibody Test, and there are more in develop-
ment, such as the mChip, a smartphone dongle that performs an 
ELISA on a small chip using microfluidics.61
Our results demonstrate excellent performance for the HIV 
component of the dual RDTs for HIV and syphilis and good 
performance for the syphilis component, similar to the perfor-
mance of single syphilis RDTs.54 62 When considering perfor-
mance, cost-effectiveness and feasibility, these tests should be 
prioritised for use in settings and among populations where HIV 
and syphilis screening are recommended, namely, antenatal care 
settings. As the screening recommendations for HIV and syphilis 
are similar in many respects, it is logical and practical to combine 
their diagnosis on a single cartridge.63 Dual RDTs for HIV and 
syphilis testing would allow same-day treatment for syphilis and 
immediate referral for HIV therapy, thus enhance the prevention 
of MTCT of HIV and syphilis.64 Dual RDTs for HIV and syphilis 
therefore represent an important measure in the elimination of 
MTCT of HIV and syphilis. This systematic review will inform 
the WHO process for developing diagnostic algorithms for the 
use of dual RDTs for HIV and syphilis diagnosis. In the interim, 
WHO has developed interim guidance for use and interpretation 
of these tests.65 Future work will be required to build a toolkit 
for programme and clinic managers, similar to the one that was 
established for rapid syphilis testing,66 which would provide 
Key messages
 ►  In studies of dual HIV/syphilis tests on a single device, the 
accuracy of HIV diagnosis remained high regardless of test 
manufacturer or whether evaluations were conducted in 
laboratory or field settings.
 ► The accuracy of syphilis testing was good (similar to single 
tests for syphilis), although not as high as HIV, in both 
laboratory and field settings and regardless of manufacturer.
 ► Dual testing for HIV and syphilis has been shown to be more 
cost-effective and more effective at preventing adverse 
pregnancy outcomes than testing for HIV alone or using 
separate RDTs for HIV and syphilis.
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guidance on planning, management and implementation of dual 
RDTs for HIV and syphilis.
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